Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease
Latest Information Update: 12 Apr 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Cardiovascular disorders
- Focus Pharmacodynamics
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 01 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 May 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2017.